LOS ANGELES--(BUSINESS WIRE)--
Glancy Prongay & Murray LLP (“GPM”), a global investors rights law firm, announces that a class action lawsuit has been filed on behalf of investors that purchased or otherwise acquired TG Therapeutics, Inc. (“TG Therapeutics” or the “Company”) (NASDAQ: TGTX) securities between June 4, 2018 and September 25, 2018, inclusive (the “Class Period”). TG Therapeutics investors have until December 3, 2018 to file a lead plaintiff motion.
If you are a shareholder who suffered a loss, click here to participate.
On September 26, 2018, TG Therapeutics announced that it could not proceed with the interim analysis of one of its leading product candidates, Ublituximab (TG-1101), following a determination by the FDA Data Safety Monitoring Board trials, that the UNITY-CLL trial data was not mature enough to continue. On this news, TG Therapeutics dropped 44% to close at $5.15 per share, thereby injuring investors.
The complaint filed in this class action alleges that the Company made false and misleading statements to the market. TG Therapeutics was engaged in cleaning the data collected from its UNITY-CLL study, which gave it an understanding of the efficacy of the combination therapy. Based on that understanding, the Company knew the study had failed to reach its goals, and therefore knew it would not be able to seek accelerated approval. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period.
Follow us for updates on Twitter: twitter.com/GPM_LLP.
If you purchased shares of TG Therapeutics during the Class Period you may move the Court no later than December 3, 2018 to ask the Court to appoint you as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to email@example.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.